| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,782,285 ) |
| | 2025 | 2025 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R00HL177831 | Inflammation-associated Autophagy Dysfunction | 000 | 1 | NIH | 3/31/2025 | $465,000 |
| | 2025 | 2025 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL177719 | Molecular and Translational Studies in Hematologic Disorders | 000 | 1 | NIH | 2/24/2025 | $1,276,908 |
| | 2025 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R00HL164888 | Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease | 000 | 3 | NIH | 12/9/2024 | $40,377 |
| | 2025 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | K99HL156058 | Inflammation-mediated platelet hyperreactivity and thrombosis | 000 | 4 | NIH | 3/26/2025 | $0 |
| | 2025 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 001 | 6 | NIH | 2/24/2025 | $0 |
| | 2025 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 6 | NIH | 11/18/2024 | $0 |
| | 2025 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R00HL164888 | Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease | 001 | 3 | NIH | 2/20/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,981,330 ) |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R00HL164888 | Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease | 000 | 3 | NIH | 8/1/2024 | $249,000 |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | K99HL156058 | Inflammation-mediated platelet hyperreactivity and thrombosis | 003 | 4 | NIH | 7/19/2024 | $202,576 |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | K99HL156058 | Inflammation-mediated platelet hyperreactivity and thrombosis | 001 | 4 | NIH | 6/29/2024 | $210,724 |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL153072 | Role of TRPM8 in Cold-stored Platelet Transfusions | 000 | 5 | NIH | 7/15/2024 | $586,949 |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 001 | 6 | NIH | 6/21/2024 | $85,897 |
| | 2024 | 2024 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 6 | NIH | 3/4/2024 | $966,348 |
| | 2024 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152066 | Comprehensive Characterization of Missense Mutants in Factor IX | 000 | 3 | NIH | 10/27/2023 | -$320,163 |
|
| Issue Date FY: 2023 ( Subtotal = $2,047,328 ) |
| | 2023 | 2023 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 5 | NIH | 2/20/2023 | $1,080,109 |
| | 2023 | 2023 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 001 | 5 | NIH | 8/10/2023 | $0 |
| | 2023 | 2023 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL153072 | Role of TRPM8 in Cold-stored Platelet Transfusions | 000 | 4 | NIH | 8/31/2023 | $598,928 |
| | 2023 | 2023 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 000 | 4 | NIH | 3/27/2023 | $657,939 |
| | 2023 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152066 | Comprehensive Characterization of Missense Mutants in Factor IX | 000 | 3 | NIH | 3/27/2023 | $0 |
| | 2023 | 2019 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL137991 | The Biology of VWF Self-Association | 000 | 3 | NIH | 11/21/2022 | -$554 |
| | 2023 | 2018 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL112633 | von Willebrand Factor in Sickle Cell Disease Pathophysiology | 000 | 7 | NIH | 2/27/2023 | -$44,099 |
| | 2023 | 2017 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL117639 | Biosynthetic and Functional Consequences of von Willebrand Disease Mutations | 000 | 5 | NIH | 10/1/2022 | -$227,555 |
| | 2023 | 2017 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL112790 | Pathobiology of Incompatible transfusion | 000 | 5 | NIH | 10/1/2022 | -$17,440 |
|
| Issue Date FY: 2022 ( Subtotal = $3,079,732 ) |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152066 | Comprehensive Characterization of Missense Mutants in Factor IX | 000 | 3 | NIH | 3/18/2022 | $367,755 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 001 | 3 | NIH | 6/6/2022 | $457,002 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 000 | 3 | NIH | 3/31/2022 | $592,535 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152066 | Comprehensive Characterization of Missense Mutants in Factor IX | 001 | 3 | NIH | 6/8/2022 | $40,862 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 001 | 4 | NIH | 6/17/2022 | $108,105 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 4 | NIH | 3/17/2022 | $972,915 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 002 | 3 | NIH | 6/17/2022 | $65,840 |
| | 2022 | 2022 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL153072 | Role of TRPM8 in Cold-stored Platelet Transfusions | 000 | 3 | NIH | 7/26/2022 | $477,739 |
| | 2022 | 2019 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL137991 | The Biology of VWF Self-Association | 000 | 3 | NIH | 12/21/2021 | $0 |
| | 2022 | 2018 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL133325 | Immune Response to RBC Antigens | 001 | 2 | NIH | 6/29/2022 | -$1,924 |
| | 2022 | 2018 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | P01HL132819 | Immunobiology of Transfusion | 001 | 2 | NIH | 6/29/2022 | -$1,098 |
| | 2022 | 2017 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL133325 | Immune Response to RBC Antigens | 000 | 1 | NIH | 6/29/2022 | $0 |
| | 2022 | 2017 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | P01HL132819 | Immunobiology of Transfusion | 000 | 1 | NIH | 6/29/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,648,640 ) |
| | 2021 | 2021 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 3 | NIH | 3/29/2021 | $1,083,722 |
| | 2021 | 2021 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL153072 | Role of TRPM8 in Cold-stored Platelet Transfusions | 000 | 2 | NIH | 7/15/2021 | $477,739 |
| | 2021 | 2021 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 000 | 2 | NIH | 3/11/2021 | $658,804 |
| | 2021 | 2021 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152066 | Comprehensive Characterization of Missense Mutants in Factor IX | 000 | 2 | NIH | 3/12/2021 | $428,767 |
| | 2021 | 2018 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | P01HL132819 | Immunobiology of Transfusion | 000 | 2 | NIH | 12/11/2020 | -$392 |
| | 2021 | 2018 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL125957 | VWF Activity: Molecular Biology, Ethnic Diversity and Disease Associations | 000 | 4 | NIH | 1/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,856,924 ) (Continued on the next page) |
| | 2020 | 2020 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R01HL152200 | von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy | 000 | 1 | NIH | 3/26/2020 | $679,475 |
| | 2020 | 2020 | BLOODWORKS | 921 TERRY AVE | SEATTLE | WA | 98104-1239 | KING | USA | R35HL145262 | Molecular and Translational Studies in Hematologic Disorders | 000 | 2 | NIH | 2/25/2020 | $1,084,583 |
|
